Citing Interest From Major Drug Makers, MedImmune Considers Sale
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech announces it is evaluating third-party offers following stockholder dissatisfaction.
You may also be interested in...
AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.
AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.
MedImmune Delays Numax BLA Pending Additional RSV Trial Data
Company hopes data from a second Phase III trial, due at summer’s end, will make the application more attractive to FDA.